文献速递胸部肿瘤放疗放疗物理与技术

BIBR1532通过增加端粒功能障碍和抑制ATM/CHK1增强非小细胞肺癌放射敏感性

BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-08-13

本研究探讨选择性端粒酶抑制剂BIBR1532对非小细胞肺癌(NSCLC)的放射增敏作用及机制。体外实验显示低浓度BIBR1532虽无直接毒性,但可显著增强放射诱导的凋亡、衰老和有丝分裂灾难;小鼠移植瘤模型中非毒性剂量BIBR1532与放疗协同抗肿瘤且未增加血液和内脏毒性。机制上,低浓度BIBR1532抑制端粒酶活性、增加放射诱导的端粒功能障碍,破坏染色体稳定性并抑制ATM/CHK1通路,损害DNA损伤修复。

要点

  • 低浓度BIBR1532无直接细胞毒性但显著增强NSCLC放射敏感性。
  • BIBR1532与放疗协同抗肿瘤且未增加血液和内脏毒性。
  • 机制涉及端粒功能障碍、染色体不稳定及ATM/CHK1通路抑制。

核心结论

  • 非毒性剂量BIBR1532通过干扰端粒酶功能有效增强NSCLC细胞放射敏感性,为临床评估BIBR1532作为放射增敏剂提供依据。

研究设计与样本

  • 体外使用CCK-8、实时荧光定量PCR和免疫荧光检测细胞增殖、端粒酶活性及端粒功能障碍诱导 foci;通过克隆存活和移植瘤实验分析BIBR1532对NSCLC细胞放射反应的影响;用Western blot、流式细胞术和衰老相关β-半乳糖苷酶染色检测细胞死亡和衰老。

主要发现

  • 较高浓度BIBR1532对NSCLC细胞呈剂量依赖性直接细胞毒性。
  • 低浓度BIBR1532对NSCLC细胞无明显毒性,但通过增强放射诱导的凋亡、衰老和有丝分裂灾难显著提高体外放疗疗效。
  • 小鼠移植瘤模型中,非毒性剂量BIBR1532与放疗协同增强抗肿瘤效果,且对血液和内脏无毒性。
  • 低浓度BIBR1532有效抑制端粒酶活性,增加放射诱导的端粒功能障碍,破坏染色体稳定性并抑制ATM/CHK1通路,损害DNA损伤修复。

临床怎么用

  • BIBR1532有望作为NSCLC放疗的放射增敏剂,但需临床评估其安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Telomerase is reactivated in non-small cell lung cancer (NSCLC), and it increases cell resistance to irradiation through protecting damaged telomeres and enhancing DNA damage repair. We investigated the radiosensitizing effect of BIBR1532, a highly selective telomerase inhibitor, and its corresponding mechanism in NSCLC. METHODS AND MATERIALS: Cell proliferation, telomerase activity, and telomere dysfunction-induced foci were measured with CCK-8 assay, real-time fluorescent quantitative polymerase chain reaction, and immunofluorescence. The effect of BIBR1532 on the response of NSCLC cells to radiation was analyzed using clonogenic survival and xenograft tumor assays. Cell death and cell senescence induced by BIBR1532 or ionizing radiation (IR), or both, were detected with western blotting, flow cytometry, and senescence-association β-galactosidase staining assay. RESULTS: We observed dose-dependent direct cytotoxicity of BIBR1532 at relatively high concentrations in NSCLC cells. Low concentrations of BIBR1532 did not appear toxic to NSCLC cells; however, they substantially increased the therapeutic efficacy of IR in vitro by enhancing IR-induced apoptosis, senescence, and mitotic catastrophe. Moreover, in a mouse xenograft model, BIBR1532 treatment synergized with IR at nontoxic dose levels promoted the antitumor efficacy of IR without toxicity to hematologic and internal organs. Mechanistically, lower concentrations of BIBR1532 effectively inhibited telomerase activity and increased IR-induced telomere dysfunction, resulting in disruption of chromosomal stability and inhibition of the ATM/CHK1 (ataxia-telangiectasia-mutated/Checkpoint kinase 1) pathway, which impaired DNA damage repair. CONCLUSIONS: Our findings demonstrate that disturbances in telomerase function by nontoxic dose levels of BIBR1532 effectively enhance the radiosensitivity of NSCLC cells. This finding provides a rationale for the clinical assessment of BIBR1532 as a radiosensitizer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ding X, Cheng J, Pang Q, et al. BIBR1532, a Selective Telomerase Inhibitor, Enhances Radiosensitivity of Non-Small Cell Lung Cancer Through Increasing Telomere Dysfunction and ATM/CHK1 Inhibition. Int J Radiat Oncol Biol Phys. 2019. PMID: 31419512. doi:10.1016/j.ijrobp.2019.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。